A Multicenter Evaluation of Ceftolozane/Tazobactam Treatment Outcomes in Immunocompromised Patients With Multidrug-Resistant Pseudomonas aeruginosa Infections

BACKGROUND: Real-world data assessing outcomes of immunocompromised patients treated with ceftolozane/tazobactam (C/T) are limited. This study evaluated treatment and clinical outcomes of immunocompromised patients receiving C/T for multidrug-resistant (MDR) Pseudomonas aeruginosa. METHODS: This was...

Descripción completa

Detalles Bibliográficos
Autores principales: Hart, Delaney E, Gallagher, Jason C, Puzniak, Laura A, Hirsch, Elizabeth B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Major Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7990512/
https://www.ncbi.nlm.nih.gov/pubmed/33796600
http://dx.doi.org/10.1093/ofid/ofab089

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7990512/
https://www.ncbi.nlm.nih.gov/pubmed/33796600
http://dx.doi.org/10.1093/ofid/ofab089

Ejemplares similares